Search

Displaying results 4181 - 4190 of 7059 in total
  1. Drug

    Dabigatran etexilate

    go.drugbank.com/drugs/DB06695
    ApprovedInvestigational

    [A177463] Dabigatran etexilate was approved by the FDA in 2010.[L6022]

    Products: Dabigatranetexilat 1A Pharma 75 mg - Hartkapseln, Dabigatranetexilat 1A Pharma 110 mg - Hartkapseln
  2. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    Remibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. … [L54101] Bruton's tyrosine kinase plays a role in B cell receptor and Fc receptor signalling, releasing histamine and pro-inflammatory mediators.

  3. Drug

    Lotiglipron

    go.drugbank.com/drugs/DB21631
    Investigational

    Lotiglipron has a monoisotopic molecular weight of 574.2 Da. … Lotiglipron is a small molecule drug. The usage of the INN stem '-glipron' in the name indicates that Lotiglipron is a glucagon-like peptide 1 receptor (GLPIR) agonist.

  4. Drug

    Doxepin

    go.drugbank.com/drugs/DB01142
    ApprovedInvestigational

    [T83] In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline … Doxepin is a psychotropic agent with antidepressant and anxiolytic properties.

    Products: DOXEPIN 10 1A PHARMA, DOXEPIN 25 1A PHARMA
  5. Drug

    Bebtelovimab

    go.drugbank.com/drugs/DB16755
    ApprovedWithdrawn

    Bebtelovimab (LY-COV1404, LY-3853113) is a human monoclonal antibody approved for emergency use in the treatment of COVID-19. … [L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients.

  6. Drug

    Onasemnogene abeparvovec

    go.drugbank.com/drugs/DB15528
    ApprovedInvestigational

    Developed by AveXis, a Novartis company,[A187253] onasemnogene abeparvovec is commonly marketed as Zolgensma®, which is available as a single-dose intravenous infusion. … muscular atrophy (SMA) and a specific mutation in the survival motor neuron 1 (SMN1) gene.

  7. Drug

    Tapinarof

    go.drugbank.com/drugs/DB06083
    ApprovedInvestigational

    It is available as a topical cream to be applied to the affected area once daily. … [A248790] Tapinarof received initial approval from the FDA in 2022.[L41845]

  8. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively. … It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.

  9. Drug

    Abemaciclib

    go.drugbank.com/drugs/DB12001
    ApprovedInvestigational

    On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed

    Categories: MATE 1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  10. Drug

    Simoctocog alfa

    go.drugbank.com/drugs/DB09108
    Approved

    It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the factor VIII in the intrinsic pathway of blood coagulation system. … plasma-derived FVIII, has been deleted and replaced by a 16 amino acid linker.